Birmingham, ALNCT06829238Now EnrollingIRB Ready

Systemic Inflammation Clinical Trial in Birmingham, AL

Access cutting-edge systemic inflammation treatment through this phase 4 clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.

Sponsored by University of Alabama at Birmingham

Quick Self-Assessment

See if you qualify for this Birmingham location

Preparing your pre-screening questions…

Expert Care in Birmingham

Access systemic inflammation specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related systemic inflammation treatment provided free

Apply for This Birmingham Location

Check if you qualify for this systemic inflammation clinical trial in Birmingham, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Birmingham

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Birmingham site if eligible
  4. 4Begin participation

About This Systemic Inflammation Study in Birmingham

This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.

Sponsor: University of Alabama at Birmingham

Who Can Participate

Inclusion Criteria

Provision of signed and dated informed consent.
Stated willingness to comply with all study procedures and availability for the study duration.
Aged 18 to 64 years old.
Weight of at least 110 lbs.
Body Mass Index (BMI) of 18.5-40. Enrollment of individuals with BMI \>40, deemed in good health, may be considered with approval.
Willingness to receive Jynneos (MPOX) and Capvaxvie vaccines.
Ability to take oral medication and willingness to adhere to the metformin treatment regimen.
History of injection opioid, amphetamine, and/or cocaine use within the past 10 years (self-report).
Use of non-prescription opioid, amphetamine, and/or cocaine within the past 30 days (self-report).
Clinically confirmed urine drug screen for opioid, amphetamine, and/or cocaine within the past 30 days.
Serum CRP \> 3 mg/dL.
Glucose level between 70-180 mg/dL (non-fasting).
Hemoglobin A1c (HbA1c) of 5.0-6.4%.
CD4 count \> 200 cells/ml.
If HIV-positive, HIV viral load \< 200 copies/ml.
If HIV-positive, on anti-retroviral therapy (ART) for \>12 months.

Exclusion Criteria

Inability to give informed consent.
Refusal or inability to have blood drawn.
Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, platelet disorder requiring precautions).
Pregnant or nursing individuals.
Diabetes mellitus.
History of severe renal impairment or eGFR \<60 mL/min/1.73m².
Creatinine clearance \<60 mL/min.
History of liver disease.
ALT/AST \> 3× the upper limit of normal.
Total bilirubin \>1.4 mg/dL.
Albumin \<3.5 g/dL.
Prothrombin \>1.5× the upper limit of normal.
AUDIT-C score ≥8.
Hemoglobin \<9.0 g/L.
Absolute neutrophil count \<1,000/mL.
Platelet count \<100,000/mL.
History of acute or chronic metabolic acidosis.
Serum bicarbonate \<22 mEq/L.
Anion gap \>10 mEq/L.
Serum lactate \>2.2 mmol/L.
Serum vitamin B12 \<250 pg/mL.
History of chronic diarrhea.
Current use of metformin or other diabetes medications.
History of myocardial infarction, endocarditis, stroke, heart failure, chronic obstructive pulmonary disease, or sepsis.
Use of medications such as furosemide, nifedipine, ranolazine, vandetanib, or cimetidine (current or within the past 30 days).
Active hepatitis B infection.
Hepatitis C infection within 6 months of study entry; individuals with prior hepatitis C must be at least 6 months post-treatment with direct-acting antivirals.
Previous receipt of Jynneos or pneumococcal vaccine within the past two years (self-report).
Severe allergic reaction to metformin, Jynneos, or Capvaxvie (self-report). Blood donations exceeding 450 mL in the 8 weeks prior to enrollment, accounting for study-related blood draws.
Any medical, psychiatric, social condition, or responsibility that, in the investigator's judgment, could interfere with study procedures.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Birmingham?

Yes, this clinical trial (NCT06829238) has an active research site in Birmingham, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Systemic Inflammation Treatment Options in Birmingham, AL

If you're searching for systemic inflammation treatment options in Birmingham, AL, this clinical trial (NCT06829238) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Birmingham research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced systemic inflammation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all systemic inflammation clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Birmingham, AL

See all multiple myeloma clinical trials recruiting in Birmingham — not just this study.

Browse Multiple Myeloma Trials in Birmingham →

Browse More Trials by Condition

Multiple Myeloma TrialsFollicular Lymphoma TrialsHeart Attack TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Birmingham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Birmingham, AL